Breast cancer

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT)

This study will look at the effect of palbociclib combined with anti-HER2 therapy plus endocrine therapy versus anti-HER2-based therapy plus endocrine therapy alone in patients with hormone receptor positive, HER2+ metastatic breast cancer.

This Phase II study is evaluating the safety and effectiveness of Stereotactic Ablative Body Radiotherapy (SABR) for the treatment of lung tumours. You may be eligible to join this study if: you are aged 18 years or above; have 1-3 lung metastases from any non-haematological primary tumour; you are medically inoperable, high risk or have decline surgery; and you have not had any previous high-dose radiotherapy to the chest region.